Patients
cancers, Tumors, active malignancies, infection, hematologic, hepatic, and renal function
CANCERS, BRAIN METASTASES, DISEASE, SOLID TUMORS, TUMORS, INFECTION, NONMELANOMA SKIN CANCER, ONCOLOGY, IN SITU CANCER
Eligible patients were ≥18 years of age and had histologically or cytologically confirmed advanced solid tumors for which standard treatments were exhausted or were no longer effective; measurable disease as per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) guidelines; Eastern Cooperative Oncology Group performance status of 0–1; and adequate hematologic, hepatic, and renal function. Patients were excluded if they had received radiotherapy to >25% of the bone marrow or had symptomatic brain metastases; other active malignancies (except for adequately treated nonmelanoma skin cancer, in situ cancer, or other cancers whose natural history or treatment did not have the potential to interfere with the safety or efficacy assessment of the study); active infection; radiotherapy, surgery, chemotherapy, targeted therapy, hormonal therapy, or an investigational drug/device within 28 days of the study start date; or concomitant use of strong CYP3A4 inhibitors/inducers or naproxen. A complete list of the inclusion and exclusion criteria is provided in the 